Neil Woodford, manager of the £6.6bn Woodford Equity Income fund, has significantly reduced exposure to former top holding AstraZeneca in order to invest in areas where he feels valuations are more attractive, such as domestic names.
Exposure to the pharmaceutical company has been gradually reduced over the past 12 months, moving from being its top holding representing 8% of the portfolio in April 2017 to just 1%, now making it the...
Working in London and Geneva
Staunch value investor
Effective 24 September
Latest edition of the print magazine online
Four-part Big Question special